All canine diagnoses

Your dog was diagnosed with Multicentric T-Cell Lymphoma. Accounts for 15-30% of canine multicentric lymphoma cases. Carries a significantly worse prognosis than B-cell lymphoma. More frequently associated with hypercalcaemia and mediastinal involvement. Compare 6 treatment options for dogs including CHOP Protocol, COP Protocol, Single-Agent Doxorubicin — with survival times, costs, and what to expect during treatment.

🐕

Multicentric T-Cell Lymphoma

WHO Stage III-V

BreedsBoxerGolden RetrieverSiberian Husky
canine

Round Cell

About This Cancer

T-cell lymphoma arises from T-lymphocytes, the white blood cells that normally coordinate immune responses and destroy infected cells. Like B-cell lymphoma, it typically presents with widespread lymph node enlargement, but T-cell lymphoma carries a significantly worse prognosis. T-cell disease accounts for roughly 15–30% of multicentric lymphoma cases in dogs and is more frequently associated with elevated blood calcium levels (hypercalcaemia), which can cause increased thirst, urination, and kidney problems as a secondary complication. The cancer tends to respond less completely to standard chemotherapy protocols, and remission times are typically shorter than for B-cell lymphoma. Boxers, Golden Retrievers, and Siberian Huskies appear to be at higher risk.

WHO Clinical Staging for Canine Lymphoma

Same staging system as B-cell. T-cell lymphoma more commonly presents with hypercalcaemia and mediastinal involvement.

Stage ISingle lymph node or single extranodal site involvement
Stage IIMultiple lymph nodes in a regional area
Stage IIIGeneralised lymph node involvement
Stage IVLiver and/or spleen involvement
Stage VBlood, bone marrow, or non-lymphoid organ involvement
Prognostic Factors(5)
T-cell phenotypeInherently worse prognosis compared to B-cell. MST approximately 50-60% of B-cell MST with same protocols.
HypercalcaemiaMore common in T-cell lymphoma. Negative prognostic indicator. Requires aggressive fluid therapy.
Thrombocytopenia at presentationParadoxically associated with longer overall survival in one study (323 vs 212 days, P=0.01)(PMID 26279153)
Histological subtypePeripheral T-cell lymphoma NOS, lymphoblastic, and clear cell subtypes carry different prognoses. Lymphoblastic T-cell lymphoma is associated with particularly aggressive behaviour and shorter survival.
Ki-67 / proliferation indexHigher Ki-67 proliferation index is associated with more aggressive disease behaviour and shorter survival. Cut-off values for prognostic stratification in T-cell lymphoma are not well established.
Minimum Workup(8 steps)
1CRITICAL WARNING: Avoid administering prednisolone/prednisone BEFORE obtaining biopsy/cytology — corticosteroids can induce multi-drug resistance (MDR) and cause rapid tumour lysis, making subsequent histopathological diagnosis difficult or impossible. Complete diagnostic workup BEFORE starting any corticosteroid therapy.
2Fine-needle aspirate with cytology
3Flow cytometry or immunohistochemistry confirming T-cell phenotype (CD3+)
4CBC with differential
5Biochemistry panel (including ionised calcium)
6Thoracic radiographs (evaluate for mediastinal mass)
7Abdominal ultrasound
8Bone marrow aspirate

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
CHOP Protocol
~8 mo (6–9)
COP Protocol
See notes
Single-Agent Doxorubicin
See notes
Lomustine (CCNU)
See notes
Prednisone Monotherapy
~1.5 mo (1–2)
T-Cell Rescue Protocols (Overview)
~2 mo (1–4)
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.